AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 283 min read$GEHC

GE HealthCare (GEHC) Q3 2026 Earnings Call Transcript

GE HealthCare (GEHC) reported Q3 2026 revenue of $5.5B, up 6.2% organically, with adjusted EBIT margin expanding to 16.6%. Growth was seen across all segments, with pharmaceutical diagnostics leading at 13.8%. The company announced the acquisition of SoFi Bioscience and a leadership change in the Patient Care Solutions business. Free cash flow was $793M, up $310M year-over-year.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 5:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
GE HealthCare (GEHC) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GEHCBullishHigh
01

Why it matters

The earnings beat and strategic acquisition provide both immediate earnings momentum and longer‑term growth potential.

02

Market read

The strong earnings and acquisition news are likely to drive GEHC stock higher and may positively influence the healthcare equipment sector.

03

What to watch

Potential integration risk of SoFi Bioscience and macro inflation pressures on input costs.

Relevance 9/10Novelty 9/10Timing: post‑earnings release today

Background

GE Healthcare is a leading provider of medical imaging, diagnostics, and digital health solutions.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

GE Healthcare reported Q3 2026 earnings with revenue $5.5B, EPS $1.34 (+25%), margin expansion and acquisition of SoFi Bioscience.

Expected impact

likely upward pressure as market prices in the earnings beat and growth guidance

Evidence & confidence

Revenue and EPS both exceeded expectations, margins improved, and a strategic acquisition was announced, providing both top‑line and strategic catalysts.

Market effects

Sector

Strong performance may lift the broader medical imaging and diagnostics sector.

Regional

Positive for US healthcare equipment makers.

Global

Reinforces confidence in demand for advanced imaging and radiopharmaceuticals worldwide.

Counterpoint

What could challenge this read

If the market had already priced in the beat, the stock could face short‑term profit‑taking.

Key entities

  • company
    GE Healthcare

    US‑listed medical technology firm (ticker GEHC).

  • company
    SoFi Bioscience

    Radiopharmaceutical developer being acquired by GE Healthcare.

Read at source← All news

StoryGE HealthCare posts strong Q3 2026 results and lifts FY‑2026 outlook

Also covered by

5 outlets

Related articles

OCT 28
$GEHCMed

GE HealthCare Technologies Inc. Q3 2026 Earnings Call Summary

GE HealthCare Technologies Inc. reported Q3 2026 earnings, raising full-year guidance for revenue growth, margins, and cash flow. The company highlighted operational improvements, strategic acquisitions, and supply chain resilience. Management expects continued momentum in 2027 despite inflation and tariff challenges, with a 14% dividend increase. Key growth areas include Advanced Imaging Solutions and Pharmaceutical Diagnostics, with a focus on high-margin products and emerging markets.

finance.yahoo.com2 min
OCT 28
$GEHCHighAI 8/10

GEHC Q3 Earnings Beat Estimates on Strong Growth, '26 View Raised

GE HealthCare (GEHC) reported Q3 2026 adjusted EPS of $1.34, beating estimates by 10.7% and rising 25.1% YoY. Revenue grew 7.2% to $5.51B, exceeding expectations. The company raised its 2026 guidance, forecasting 4% organic revenue growth and adjusted EPS of $4.95-$5.05. Shares rose 8.3% in pre-market trading.

zacks.com3 min
OCT 28
$GEHCHighAI 8/10

GE HealthCare (GEHC) stock trades up, here is why

GE HealthCare (GEHC) stock rose 7.2% after Q3 2026 results beat expectations, with revenue up 7.2% and EPS up 39.1%. The company raised its full-year guidance, citing strong demand for healthcare equipment. GEHC is down 7.8% YTD but up 27.2% since its IPO.

tradingview.com2 min